Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014092 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
A Phase 2 study, sponsored by Saint Francis Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00014092 is a Phase 2 study that has completed, run by Saint Francis Hospital.
The verdict
NCT00014092, a Phase 2 study, has completed, sponsored by Saint Francis Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interleukin-2 and interferon alfa stimulate a person's white blood cells to kill cancer cells or may interfere with the growth of cancer cells. Combining chemotherapy with biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide followed by sargramostim, interleukin-2, and interferon alfa in treating patients who have stage IV melanoma that cannot be treated with surgery.
Interventions
- DRUG temozolomide
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014092
The ClinicalTrials.gov registry entry for NCT00014092 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Saint Francis Hospital, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which temozolomide is the first listed.
NCT00014092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014092 about?
NCT00014092 is a clinical study titled "Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interleukin-2 and interferon alfa stimulate a person's white blood cells to kill cancer cells or may interfere with the growth of cancer cells. Combini...
What is the current status of trial NCT00014092?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00014092?
The interventions under investigation include: temozolomide (DRUG), aldesleukin (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00014092?
This trial is sponsored by Saint Francis Hospital, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.